Verona Pharma stock jumps 20% on $10B Merck deal—can FDA-approved Ohtuvayre reshape COPD care?
What is Ohtuvayre and why does it matter?
Live Events
How much is Merck paying and what does it mean for shareholders?
What's next for Verona Pharma and its future under Merck?
What does this mean for the future of COPD treatment?
FAQs:
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
Verona Pharma stock surged 20% on Wednesday after Merck announced it's buying the British biotech company in a $10.8 billion deal. Merck, through a subsidiary, will pay $107 per American depositary share for Verona Pharma, a company focused on respiratory treatments. This move follows the FDA's recent approval of Verona's drug Ohtuvayre, which is used to manage chronic obstructive pulmonary disease (COPD) in adults.As per the joint announcement, the deal is expected to close in Q4 2025, pending regulatory approval from the U.K. authorities. Meanwhile, Verona's U.S.-listed shares were up 20% at $104.55 in premarket trading, while Merck's stock was slightly higher, rising 0.2%.Merck's decision to acquire Verona Pharma comes just weeks after the U.S. Food and Drug Administration (FDA) granted approval to Ohtuvayre, Verona's lead drug for COPD. Merck CEO Robert M. Davis called Ohtuvayre a strong fit for the company's growing cardio-pulmonary portfolio, saying the drug "complements and expands" Merck's existing treatments.This acquisition allows Merck to strengthen its position in respiratory care, a space it's been eyeing for future growth. With Ohtuvayre already FDA-approved and additional clinical trials underway, Merck likely saw this as a well-timed opportunity to buy into a promising treatment pipeline.Ohtuvayre, Verona Pharma's flagship therapy, is designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD)—a condition that affects over 16 million adults in the U.S. alone, according to the CDC.The drug received FDA approval in June 2024, and it is now being evaluated for additional use in non-cystic fibrosis bronchiectasis, which is another hard-to-treat lung condition. This broader application potential makes Ohtuvayre a valuable long-term asset, not just a single-treatment drug.Given the increasing number of COPD cases and limited long-term therapies in the market, Ohtuvayre could be a key differentiator for Merck in this niche.The deal values Verona Pharma at approximately $10.8 billion, with Merck agreeing to pay $107 per American depositary share (ADS). This represents a ~24% premium over Verona's recent trading price before the announcement.Shareholders of Verona saw an immediate benefit, with stock climbing 20% to $104.55 in early trading hours. The offer price also gives current holders an attractive exit or long-term upside if they believe in Merck's execution capabilities.This acquisition follows a trend of pharma giants turning to biotech startups for fresh innovation rather than developing everything in-house—a strategy that saves time and accelerates go-to-market opportunities.Once the acquisition is finalized—expected sometime in Q4 2025, pending UK regulatory approval—Verona will operate as part of Merck's growing respiratory division. Merck will likely support ongoing trials for Ohtuvayre's use beyond COPD, particularly in non-cystic fibrosis bronchiectasis.Additionally, Merck may integrate Verona's research teams, technologies, and pipelines into its broader global infrastructure to maximize development and commercial potential.This move not only gives Merck access to a revenue-generating asset, but also the scientific expertise and momentum Verona has built around respiratory innovation.This acquisition could mark a turning point in how COPD and related pulmonary diseases are treated. With Merck's global reach and Verona's product innovation, the hope is for more effective, accessible, and scalable treatments.In a market where demand for chronic disease therapies is rising sharply—especially in aging populations—Merck's move positions it well for the long term.As more clinical data becomes available for Ohtuvayre's extended applications, both patients and investors will be watching closely to see how this partnership unfolds.The Verona Pharma stock jump reflects strong investor confidence in Merck's $10B bet on respiratory care. With Ohtuvayre already FDA-approved and more indications under trial, this acquisition could reshape Merck's portfolio—and possibly the future of COPD treatment worldwide.A: Merck bought Verona to expand its COPD drug pipeline with FDA-approved Ohtuvayre.A: Verona develops treatments for COPD and other lung conditions like bronchiectasis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
an hour ago
- NDTV
"One Of The Craziest Moments Of My Life": Akhil Patel On Serving Chai To PM Modi And Starmer
Indian-origin tea entrepreneur Akhil Patel had a day to remember at Chequers, the official country residence of the UK Prime Minister, on July 24. Mr Patel served a steaming cup of masala chai to Prime Minister Narendra Modi and his British counterpart Keir Starmer. Photographs shared by PM Modi on X (formerly Twitter) captured both leaders waiting for their tea at Patel's stall. Dressed in a traditional kurta and Nehru jacket, Mr Patel was captured pouring masala chai from a kettle into paper cups. 'Chai Pe Charcha' with PM Keir Starmer at stronger India-UK ties! @Keir_Starmer — Narendra Modi (@narendramodi) July 24, 2025 Now, in an Instagram clip, the founder of Amala Chai gave his followers 'a quick recap of a surreal day'. 'I just got on Modi's Instagram!' he began, clearly astonished. Detailing the invitation, Mr Patel said he was asked to serve tea at Chequers 'to celebrate the UK-India free trade deal.' 'As one of the few selected brands there, little did I know I'd be serving chai to huge UK and Indian ministers and Modi and Starmer,' he said. Among those who visited his stall were UK Business Secretary Jonathan Reynolds and Health Secretary Wes Streeting. 'They were loving it, coming back for multiple cups,' said Patel, adding that even India's National Security Advisor Ajit Doval and External Affairs Minister S Jaishankar sampled his tea. Recalling the high point of the day, Patel said, 'Then the big boys started coming my way, walking by the side of me and standing right in front of me, asking for a cup of chai.' He was referring to PM Modi and Keir Starmer. 'I served the chai, and then I dropped the line, 'from one chaiwala to another',' he added. 'Possibly one of the craziest moments of my life, I just served chai to Modi and Starmer, and Starmer loved it,' he added. His Instagram caption read, 'A quick recap of a surreal day. Yesterday, I was invited by @10downingstreet to serve chai at Chequers — to @narendramodi, @keirstarmer, and Indian & UK ministers. Can we just take a moment to realise how mad that is? There I was, in the UK Prime Minister's house, serving masala chai — and not one person wanted coffee. From one chaiwala to another, that was a special day. Right… I'm getting off the internet now to make a cup of chai.' View this post on Instagram A post shared by Amala Chai | Masala Chai (@amala_chai) In 2019, inspired by his grandma's recipe, he founded Amala Chai. Described as "Chai That Feels Like Home," the brand's masala chai begins at the source, with single-origin tea and spices from family farms in Assam and Kerala. Since its launch six years ago, Patel's Amala Chai has grown and now serves customers at five locations across London.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
India unlikely to allow US imports of GM agri products under trade deal
India is unlikely to allow American imports of genetically modified (GM) corn and soybeans, under the trade agreement that India and the United States (US) are currently negotiating, a source aware of the matter indicated. 'Some things are a matter of principle,' the source said, citing the government's position on the matter. Under the trade deal negotiations, market access for agricultural products has been one of the key demands from the US. It has also been one of the most contentious issue between both countries. Even in the past, the US Trade Representative (USTR) had pointed out several countries', including India's rules on GM products as non-tariff barriers. Last month, affiliates of the Sangh Parivar have said that the India-US trade agreement is unlikely to happen if America continues to be 'stubborn' about securing market access for genetically modified (GM) crops, Business Standard had reported. In the past, The Bharatiya Kisan Sangh (BKS) and Swadeshi Jagran Manch (SJM) had flagged the issue that concessions to the United States (US) in the agriculture sector, including dairy products, will have ramifications for the country's food security. Government officials had earlier said that the sixth round of negotiations with the US will take place in the second half of August — limiting the possibility of an interim trade deal over the next few days —before August 1. US President Donald Trump has set August 1 as a deadline for double-digit reciprocal tariffs to kick in. India could face up to 26 per cent reciprocal tariff from August 1 if no agreement for an interim is reached by then.
India.com
2 hours ago
- India.com
Bad news for Deepinder Goyal as Maharashtra govt takes big decision on Blinkit, Zepto after..., says will continue to...
(File) In more trouble for quick commerce majors Zepto and Blinkit amid the controversy surrounding their dark stores in Maharashtra, the state government has announced that it would continue regular inspections of these units to ensure cleanliness and other mandatory standards are being followed. The development comes after the Maharashtra Food and Drug Administration (FDA) ordered the closure of dark stores of both Zepto and Blinkit in early June for allegedly violating hygiene standards. The state suspended the food license of a Zepto dark store in Dharavi, while a similar facility of Blinkit was shuttered in Pune. Why FDA took action against Zepto and Blinkit? Last month, based on a consumer complaint, the Maharashtra raided a Blinkit dark store, run by Darkstore Services near Mitcon College in Pune's Balewadi area, and found that the facility was operating without a food safety license, in violation of the Food Safety and Standards Act, 2006. Apart from lack of a license, several other gross violations of hygiene standards were found during the FDA inspections, such as pieces of food items lying on the floor, workers handling consumables without headgear, etc. Following the revelation, the Joint Commissioner (Food) ordered the store operator to immediately halt all food- related activities until it obtains a valid food license from authorities. In Zepto's case, the FDA cancelled the license of its Dharavi facility for non-compliance with food standards. As per the FDA, Zepto's Dharavi dark store was shuttered for violating several regulations, including Food Safety and Standards Act, 2006 and the Food Safety and Standards (Licensing and Registration of Food Businesses) Regulations, 2011, according to a report by NDTV Profit. According to the agency, gross violations of food standards norms were found at Zepto's Dharavi facility, including fungal growth in certain food articles, and food products stores near stagnant water, which indicated poor hygiene as cold storage rules were flouted. The inspection also discovered the facility's floors were wet and filthy, and food items were stored in a disorganized and unsanitary manner, including directly on the floor. The state FDA had also found norms violations during inspections at Zepto facilities in Bhiwandi, Bandra West and Borivali. What happened to these stores after FDA action? According to Moneycontrol report, the Zepto and Blinkit have reopened their dark stores after acquiring the necessary permissions from authorities. 'Blinkit and Zepto have made the necessary changes. We had sent them a letter clearly stating that all their stores should follow the cleanliness and rules. They have assured us that these rules are now being followed completely. However, we are constantly checking whether everything is being implemented properly or not,' the report quoted Maharashtra's Minister of State for Food and Civil Supplies Yogesh Kadam as saying.
